News stories about Amgen (NASDAQ:AMGN) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amgen earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 47.0484030070029 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Q4 2018 EPS Estimates for Amgen, Inc. (AMGN) Raised by Analyst (americanbankingnews.com)
- Active Mover – Amgen Inc (NASDAQ: AMGN) – Alpha Beta Stock – Alpha Beta Stock (alphabetastock.com)
- Guide to Analyst Recommendations:: Amgen Inc. (AMGN) – Nasdaq Chronicle (nasdaqchronicle.com)
- It may surprise you: Amgen Inc., (NASDAQ: AMGN), WEC Energy Group, Inc., (NYSE: WEC); – TNN (tradingnewsnow.com)
- Snapshot of Recent Traded Stock Amgen Inc. (AMGN) 7.41% off from 200- SMA – Nasdaq Chronicle (nasdaqchronicle.com)
A number of research analysts have weighed in on AMGN shares. Oppenheimer restated a “buy” rating and issued a $205.00 price objective on shares of Amgen in a report on Thursday, November 30th. Cann restated a “buy” rating and issued a $205.00 price objective on shares of Amgen in a report on Thursday, November 30th. Goldman Sachs downgraded Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. Finally, Mizuho set a $192.00 target price on Amgen and gave the stock a “buy” rating in a research note on Thursday, December 28th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $191.72.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.03 by ($0.14). The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.89 EPS. research analysts forecast that Amgen will post 13.25 EPS for the current fiscal year.
Amgen announced that its board has authorized a stock repurchase program on Thursday, February 1st that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the medical research company to reacquire shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be paid a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a yield of 2.89%. The ex-dividend date is Wednesday, May 16th. Amgen’s payout ratio is 205.45%.
In related news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $189.75, for a total transaction of $289,368.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have sold 4,575 shares of company stock valued at $838,064. 0.19% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/19/amgen-amgn-getting-somewhat-positive-media-coverage-analysis-finds/2019910.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.